As of late, it has definitely been a great time to be an investor in Aerie Pharmaceuticals, Inc.
We certainly think that this might be the case, particularly if you consider AERI’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as AERI has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.